News from Tokyo Headquarters

Fujifilm to Expand its Viral Vector CDMO Services to Europe

Fujifilm wins Good Design Award with 27 products in a wide range of business fields

Fujifilm Concludes a Manufacturing Contract Agreement with VLP Therapeutics, for a COVID-19 Vaccine Formulation

Centus Biotherapeutics Receives European Marketing Authorization for Equidacent^®, Biosimilar Avastin^®

Fujifilm launches droplet-shielding Mouthpiece “B1” and Endoscope Cover “P1”

Anti-influenza drug Avigan^® Tablet
Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

To realize a new therapeutic option for neuroendocrine tumors
Domestic marketing approval application filed for new radiopharmaceutical F-1515 (FUJIFILM Toyama Chemical)

FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate 

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio^® (adalimumab-fkjp)

Fujifilm partners with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan

Fujifilm Kyowa Kirin Biologics Announces Approval of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan

Fujifilm to invest 100 billion yen (928 million USD) to expand its large scale biologics production facility in Denmark

Fujifilm’s New AI-based Technology for Lung Nodule Detection Now Approved for Use in Japan

Fujifilm collaborates with Merck & Co., Inc., Kenilworth, N.J., U.S.A.  in a clinical trial for advanced solid tumor in combination therapy of FF-10832, a liposome drug candidate with KEYTRUDA^® (pembrolizumab)

Fujifilm to develop AI-based technology to aid COVID-19-induced pneumonia diagnosis and assess the effectiveness of treatments

FUJIFILM Toyama Chemical starts a Phase I Clinical Trial of
FF-21101 for the Treatment of Advanced Solid Tumors in Japan (FUJIFILM Toyama Chemical Co., Ltd.)

Fujifilm accelerates production of its influenza antiviral drug “Avigan^® Tablet” for COVID-19

Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan^® Tablet” for COVID-19 patients in the U.S.